Hydroxysafflor Yellow A Alleviates Lipopolysaccharide-Induced Acute Respiratory Distress Syndrome in Mice

Zhang, Yadan; Song, Lijuan; Pan, Ruiyan; Gao, Jianwei; Zang, Baoxia; Jin, Ming

doi:10.1248/bpb.b16-00329

Cited by 22 publications

(19 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results suggested that HSYA has protective effects in dopaminergic neurons induced by LPS, and the mechanisms may be associated with the inhibition of inflammatory responses [62]. HSYA (14,28, and 56 mg/kg) was intraperitoneally injected to review lipopolysaccharide (LPS)-induced acute respiratory distress syndrome in mice [63]. Safflower yellow (SY) was shown to exert an anti-inflammatory effect on BV2 microglia [64].…”

Section: Anti-inflammatory Effectsmentioning

confidence: 99%

A Metabolic Perspective and Opportunities in Pharmacologically Important Safflower

et al. 2020

View full text Add to dashboard Cite

Safflower (Carthamus tinctorius L.) has long been grown as a crop due to its commercial utility as oil, animal feed, and pharmacologically significant secondary metabolites. The integration of omics approaches, including genomics, transcriptomics, metabolomics, and proteomics datasets, has provided more comprehensive knowledge of the chemical composition of crop plants for multiple applications. Knowledge of a metabolome of plant is crucial to optimize the evolution of crop traits, improve crop yields and quality, and ensure nutritional and health factors that provide the opportunity to produce functional food or feedstuffs. Safflower contains numerous chemical components that possess many pharmacological activities including central nervous, cardiac, vascular, anticoagulant, reproductive, gastrointestinal, antioxidant, hypolipidemic, and metabolic activities, providing many other human health benefits. In addition to classical metabolite studies, this review focuses on several metabolite-based working techniques and updates to provide a summary of the current medical applications of safflower.

show abstract

Section: Anti-inflammatory Effectsmentioning

confidence: 99%

A Metabolic Perspective and Opportunities in Pharmacologically Important Safflower

et al. 2020

View full text Add to dashboard Cite

show abstract

“…To treat ALI mice, SYA (ChromaDex, Irvine, CA, USA), HSYA (Santa Cruz, Dallas, TX, USA) and AHSYB (Nature Standard, Shanghai, China) was dissolved in saline and intraperitoneally administered immediately after the injection of LPS. All these three compounds were given at 5 × 10 -5 mol/kg in 400 μl saline [17]. The materials required for the experiment were obtained after 24 hours.…”

Section: In Vivo Experimentsmentioning

confidence: 99%

Three Ingredients of Safflower Alleviate Acute Lung Injury and Inhibit NET Release Induced by Lipopolysaccharide

Wang

Guo

Wen

et al. 2020

Mediators of Inflammation

View full text Add to dashboard Cite

Xuebijing injection is a Chinese herb compound to treat sepsis in China, but it contains many different kinds of components, and each component may have different effects in treating sepsis. The present study was performed to investigate the effect of three ingredients of Xuebijing, safflor yellow A (SYA), hydroxysafflor yellow A (HSYA), and anhydrosafflor yellow B (AHSYB), in lipopolysaccharide- (LPS-) induced acute lung injury (ALI). LPS (10 mg/kg) was injected intratracheally to induce acute lung injury in mice, which were then treated with SYA, HSYA, and AHSYB. The blood, bronchoalveolar lavage fluid (BALF), and lung tissues were collected to detect degree of lung injury, level of inflammation, and neutrophil extracellular traps (NETs). In vitro experiments were performed using HL-60 cells stimulated with phorbol myristate acetate (PMA). Lung injury induced by LPS was alleviated by SYA, HSYA, and AHSYB as demonstrated by the histopathologic test. The three components inhibit LPS-induced elevation of the levels of inflammatory factors and wet-to-dry weight ratio as well as the amount of protein and cells in the BALF. They also induced a remarkably less overlay of myeloperoxidase (MPO) and histone in the immunofluorescence assay and reduced level of MPO-DNA complex in plasma. The in vitro assay showed a similar trend that the three components inhibited PMA-induced NET release in neutrophil-like HL-60 cells. Western blot demonstrated that phosphorylation of c-rapidly accelerated fibrosarcoma (c-Raf), mitogen-activated protein kinase ERK kinase (MEK), and extracellular signal-regulated kinase (ERK) in the lungs of LPS-challenged mice, and PMA-treated HL-60 cells were all significantly reduced by SYA, HSYA, and AHSYB. Therefore, our data demonstrated that three components of XBJ, including SYA, HSYA, and AHSYB, showed a protective effect against LPS-induced lung injury and NET release.

show abstract

“…The further investigation demonstrated that intraperitoneal injection of LPS to the mice resulted in upregulation of protein expressions of TLR4, myeloid differentiation factor 88 (MyD88) and Toll/IL-1 receptor- (TIR-) domain-containing adapter-inducing interferon- β (TRIF) and phosphorylation of MAPKs, translocation of NF- κ B/p65, and downregulation of I κ B- α , all of which could be deteriorated by HSYA [ 77 ]. Zhang et al observed the negative influence of HSYA on the binding of LPS to the cell membrane receptor in the LPS-caused ARDS mice model [ 78 ]. And injection of HYSA alleviated the mRNA and protein levels of Col I, type III collagen (Col III), α -SMA, myeloid differentiation-2 (MD-2), and cluster of differentiation 14 (CD14) as well as inflammatory factors in plasma or lung and the collagen deposition in lung via suppressing the TLR4/NF- κ B pathway.…”

Section: Pharmacologymentioning

confidence: 99%

“…And injection of HYSA alleviated the mRNA and protein levels of Col I, type III collagen (Col III), α -SMA, myeloid differentiation-2 (MD-2), and cluster of differentiation 14 (CD14) as well as inflammatory factors in plasma or lung and the collagen deposition in lung via suppressing the TLR4/NF- κ B pathway. The in vivo test demonstrated the inhibitory effect of HYSA on the specific binding of LPS to receptors on A549 or Eahy926 cell membranes, suggesting the TLR4 receptor a target of HSYA on the cell membrane [ 78 ].…”

Section: Pharmacologymentioning

confidence: 99%

Hydroxysafflor Yellow A: A Promising Therapeutic Agent for a Broad Spectrum of Diseases

Feng

Peng

2018

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Hydroxysafflor yellow A (HSYA) is one of the major bioactive and water-soluble compounds isolated from Carthami Flos, the flower of safflower (Carthamus tinctorius L.). As a natural pigment with favorable medical use, HSYA has gained extensive attention due to broad and effective pharmacological activities since first isolation in 1993. In clinic, the safflor yellow injection which mainly contains about 80% HSYA was approved by the China State Food and Drug Administration and used to treat cardiac diseases such as angina pectoris. In basic pharmacology, HSYA has been proved to exhibit a broad spectrum of biological effects that include, but not limited to, cardiovascular effect, neuroprotection, liver and lung protection, antitumor activity, metabolism regulation, and endothelium cell protection. Although a great number of studies have been carried out to prove the pharmacological effects and corresponding mechanisms of HYSA, a systemic review of HYSA has not yet been seen. Here, we provide a comprehensive summarization of the pharmacological effects of HYSA. Together with special attention to mechanisms of actions, this review can serve as the basis for further researches and developments of this medicinal compound.

show abstract

Hydroxysafflor Yellow A Alleviates Lipopolysaccharide-Induced Acute Respiratory Distress Syndrome in Mice

Cited by 22 publications

References 18 publications

A Metabolic Perspective and Opportunities in Pharmacologically Important Safflower

A Metabolic Perspective and Opportunities in Pharmacologically Important Safflower

Three Ingredients of Safflower Alleviate Acute Lung Injury and Inhibit NET Release Induced by Lipopolysaccharide

Hydroxysafflor Yellow A: A Promising Therapeutic Agent for a Broad Spectrum of Diseases

Contact Info

Product

Resources

About